A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
Recruiting · NCT06418412 · Observational (researchers observe without assigning treatment) · Lead sponsor: National Cancer Centre, Singapore
View the official record on ClinicalTrials.gov →What this trial is about
There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies. This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.
Who can take part
Age range
21 Years to 99 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Histologically confirmed advanced NSCLC
- Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation
- Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)
- Male or female adults, age as defined by local regulations
Exclusion criteria
- \. Patients without an EGFR exon 20 insertion mutation
Where it is running
3 locations listed.
- Seoul National University Hospital - Seoul, South Korea
- National Cancer Centre, Singapore - Singapore, Singapore
- National Taiwan University Hospital - Taipei, Taiwan